IP Library Granted Patent US 8,263,356
Granted Patent B2
US 8,263,356 · App. 11/464,378 · Granted Sep 11, 2012

Antibodies and methods for predicting dental caries

Assignee: University of Rochester
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,356
App. No.
11/464,378
Granted
Sep 11, 2012
Kind
B2
Abstract

The present invention relates to antibodies, binding portions thereof, or probes that bind specifically to glucosyltransferase enzymes, and uses of these agents for detecting glucosyltransferase enzyme(s) in a sample and for diagnosing predisposition of a human child to early childhood caries. The present invention also relates to a kit for detecting a glucosyltransferase enzyme in an oral sample from an animal.

Claims (12)

1. A method of diagnosing predisposition of a human child to early childhood caries, said method comprising:

providing an antibody that specifically binds to a glucosyltransferase B (GtfB) enzyme from a cariogenic Streptococcus;

obtaining a saliva sample from a human child prior to onset of carious lesions;

centrifuging the obtained saliva sample to produce a clarified saliva sample;

contacting the antibody with the clarified saliva sample under conditions effective to yield a detectable signal if the GtfB enzyme is present in the clarified saliva sample and if the antibody binds to the GtfB enzyme; and

quantifying the amount of GtfB enzyme in the clarified saliva sample based on the detectable signal, wherein an increase in the amount of GtfB enzyme present in the clarified saliva sample, as compared to an amount of GtfB enzyme present in a clarified saliva sample from a caries-free human child, indicates that the human child is predisposed to early childhood caries.

2. The method according to claim 1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a mono-specific polyclonal antiserum, and combinations thereof.

3. The method according to claim 1 , wherein the detectable signal is selected from the group consisting of an immunochemical signal, a fluorescent signal, a radioactive signal, a nuclear magnetic resonance active signal, a luminescent signal, and a chromophore signal.

4. The method according to claim 1 , wherein the GtfB enzyme is from Streptococcus mutans.

5. The method according to claim 1 , wherein the human child is under 8 years of age.

6. The method according to claim 1 , wherein the human child is under 6 years of age.

7. The method according to claim 1 , wherein the human child is under 4 years of age.

Assignments (2)
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Sep 18, 2008
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021548/0572 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2006
From: BOWEN, WILLIAM H.; VACCA SMITH, ANNE; BERKOWITZ, ROBERT
To: UNIVERSITY OF ROCHESTER
Reel/Frame 018666/0434 →
Continuity (2)
Provisional Application 60707701 · Aug 12, 2005
Related Publication 20070065886A1 · Mar 22, 2007